Evidence map›Paper›PMID 30701374›Full record

ArticleCancer causes & control : CCC2019

First-year weight loss with androgen-deprivation therapy increases risks of prostate cancer progression and prostate cancer-specific mortality: results from SEARCH.

Kagan Griffin, Ilona Csizmadi, Lauren E Howard, Gina-Maria Pomann, William J Aronson, Christopher J Kane, Christopher L Amling, Matthew R Cooperberg, Martha K Terris, Jennifer Beebe-Dimmer and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer causes & control : CCC, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. [Association Between Different Modes of Respiratory Support and Feeding Intolerance in Preterm Infants: A Retrospective Cohort Study].Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition · 2023
    Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Kagan GriffinUrology Section, Department of Surgery, Veterans Affairs Medical Centers, Durham, NC, USA.
Ilona CsizmadiDivision of Urology, Department of Surgery, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Lauren E HowardUrology Section, Department of Surgery, Veterans Affairs Medical Centers, Durham, NC, USA.
Gina-Maria PomannDepartment of Biostatistics and Bioinformatics, Duke University School of Medicine, Durham, NC, USA.
William J AronsonDepartment of Urology, University of California at Los Angeles Medical Center, Los Angeles, CA, USA.
Christopher J KaneDivision of Urology, Department of Surgery, University of California at San Diego Medical Center, San Diego, CA, USA.
Christopher L AmlingDivision of Urology, Department of Surgery, Oregon Health & Science University, Portland, OR, USA.
Matthew R CooperbergDepartment of Urology, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, USA.
Martha K TerrisUrology Section, Division of Surgery, Veterans Affairs Medical Center and Division of Urologic Surgery, Department of Surgery, Medical College of Georgia, Augusta, GA, USA.
Jennifer Beebe-DimmerDepartment of Oncology, Wayne State University School of Medicine, Detroit, MI, USA.
Stephen J FreedlandUrology Section, Department of Surgery, Veterans Affairs Medical Centers, Durham, NC, USA. stephen.freedland@cshs.org.

Funding

UCLA SPORE IN PROSTATE CANCERP50CA092131 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI REITER, ROBERT E · 2002 to 2023
$42.6M
Role of GPR120 and Macrophages in Dietary Omega-3 Fatty Acid Inhibition of Prostate CancerR01CA231219 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI ARONSON, WILLIAM J, COHEN, PINCHAS · 2018 to 2022
$2.1M
Midcareer Investigator AwardK24CA160653 · NCI · DUKE UNIVERSITY · PI FREEDLAND, STEPHEN JAY · 2012 to 2016
$877k
NCI NIH HHS K24 CA160653NCI NIH HHS P50 CA092131NCI NIH HHS P50CA92131NCI NIH HHS R01 CA231219NIH HHS K24CA160653
6 · The paper itself

Abstract

purposeWe aimed to study the associations between androgen-deprivation therapy (ADT)-induced weight changes and prostate cancer (PC) progression and mortality in men who had undergone radical prostatectomy (RP).

methodsData from the Shared Equal Access Regional Cancer Hospital (SEARCH) cohort were used to study the associations between weight change approximately 1-year post-ADT initiation and metastases, castration-resistant prostate cancer (CRPC), all-cause mortality (ACM), and PC-specific mortality (PCSM) in 357 patients who had undergone RP between 1988 and 2014. We estimated hazard ratios (HR) and 95% confidence intervals (95% CI) using covariate-adjusted Cox regression models for associations between weight loss, and weight gains of 2.3 kg or more, and PC progression and mortality post-ADT.

resultsDuring a median (IQR) follow-up of 81 (46-119) months, 55 men were diagnosed with metastases, 61 with CRPC, 36 died of PC, and 122 died of any cause. In multivariable analysis, weight loss was associated with increases in risks of metastases (HR 3.13; 95% CI 1.40-6.97), PCSM (HR 4.73; 95% CI 1.59-14.0), and ACM (HR 2.16; 95% CI 1.25-3.74) compared with mild weight gains of ≤ 2.2. Results were slightly attenuated but remained statistically significant in analyses that accounted for competing risks of non-PC death. Estimates for the associations between weight gains of ≥ 2.3 kg and metastases (HR 1.58; 95% CI 0.73-3.42), CRPC (HR 1.33; 95% CI 0.66-2.66), and PCSM (HR 2.44; 95% CI 0.84-7.11) were elevated, but not statistically significant.

conclusionsOur results suggest that weight loss following ADT initiation in men who have undergone RP is a poor prognostic sign. If confirmed in future studies, testing ways to mitigate weight loss post-ADT may be warranted.

Indexed as

Weight LossAgedAndrogen AntagonistsBody WeightCancer Care FacilitiesCohort StudiesDisease ProgressionFollow-Up StudiesHumansMaleMiddle AgedPrognosisProportional Hazards ModelsProstatectomyProstatic NeoplasmsAndrogen AntagonistsAndrogen-deprivation therapyMetastasesProstate cancerProstate cancer-specific mortalityWeight gainWeight loss

Identifiers

PMID30701374
PMCPMC6599459

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.